Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.
about
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancerVitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolismAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for the long term treatment of venous thromboembolism in patients with cancerAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesFixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewVitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.Dalteparin sodium.Low-molecular-weight heparins: weeks or months instead of days of treatment.Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring.Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months.Management of thrombosis in cancer: primary prevention and secondary prophylaxis.Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.Deep vein thrombosis in cancer: the scale of the problem and approaches to management.Thrombosis: simplified.Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis.Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.Diagnosis and anticoagulant treatment.Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis.Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins.Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline.
P2860
Q24194904-107B7D8E-844A-49CD-884B-4F28C9E7BE57Q24198032-7E5E4FD0-98C4-4CB2-B33A-50B7FA94D349Q24236620-C47DA2C2-4D76-4758-ABC8-E317E0B2EBF5Q24243286-B5EDD4E1-EE5C-4941-8EA7-B5CF74E8391BQ24633053-078E20CC-6BC1-408F-9720-6E1F080E39E4Q33362095-88629C8F-379D-4CF1-88A5-6A21EEB5448CQ33380411-3BA75B73-2BFC-486D-BB9C-CEB62C042A99Q34062340-D657F8F8-4CC9-4F6D-BDBD-FEB7E986B710Q34390254-6D7C8DEB-FFE8-47FE-8786-9BD4A6555997Q34430449-4ACB6A61-26D5-4A25-A9BF-E9F0E41B5561Q34437785-D779A719-F507-4C65-9EA3-8A05D7B15655Q35181616-15B8624F-03C1-4220-BE4F-57A6B11A4BB0Q35206751-4F63F471-A6A3-47DD-A552-A76199526C9FQ35624232-1DD31899-541D-4E67-87E0-92A9D54CD154Q35975553-E8B2495D-2736-4B91-A662-82B4B2B15DE9Q36018537-E0EB695F-B0D9-4017-9915-B0257B73EE01Q36062161-0F8938F1-FA91-423D-BE9A-FFBEF15947D5Q36085302-32D88FBA-FAA3-4FC2-9D22-FE0B6F3486B5Q37998001-0CE31187-2937-45B5-B756-7D2A000AE2BFQ38224507-390698C1-EC06-47D3-85D0-4F49816A3896Q38664988-3D02923A-7D4A-4735-9986-001EAEDA149FQ44604237-A1BD15A5-47A9-40C4-85EB-EFFD90563915Q45847579-8D1F33AC-C895-4673-900F-1BFFA8026F81Q46428749-B10E1C84-C295-4821-8D72-D25FF99FAFF9Q46917499-CC63FB43-D0D5-4A63-8F78-B4AFBFBA93F0Q47188579-C154D990-FAF7-4834-B5EC-16A81322C265Q48015257-B41AB55D-1E20-41EB-BC07-F275436572CC
P2860
Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Low-molecular-weight heparin v ...... oembolism: a randomized trial.
@en
Low-molecular-weight heparin v ...... oembolism: a randomized trial.
@nl
type
label
Low-molecular-weight heparin v ...... oembolism: a randomized trial.
@en
Low-molecular-weight heparin v ...... oembolism: a randomized trial.
@nl
prefLabel
Low-molecular-weight heparin v ...... oembolism: a randomized trial.
@en
Low-molecular-weight heparin v ...... oembolism: a randomized trial.
@nl
P2093
P2860
P356
P1476
Low-molecular-weight heparin v ...... oembolism: a randomized trial.
@en
P2093
E Melissari
R A Edmondson
V V Kakkar
P2860
P2888
P304
521-6; discussion 526-7
P356
10.1007/S002689900081
P577
1996-06-01T00:00:00Z